Kayne Anderson Rudnick Investment Management LLC Sells 6,695 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Kayne Anderson Rudnick Investment Management LLC cut its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 4.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,902 shares of the company's stock after selling 6,695 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned approximately 0.16% of IDEXX Laboratories worth $53,707,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MetLife Investment Management LLC increased its holdings in IDEXX Laboratories by 0.3% during the 4th quarter. MetLife Investment Management LLC now owns 25,245 shares of the company's stock worth $10,437,000 after purchasing an additional 85 shares in the last quarter. Norinchukin Bank The grew its holdings in IDEXX Laboratories by 9.0% during the fourth quarter. Norinchukin Bank The now owns 5,594 shares of the company's stock worth $2,313,000 after buying an additional 460 shares in the last quarter. Ossiam raised its position in IDEXX Laboratories by 28.2% in the 4th quarter. Ossiam now owns 5,028 shares of the company's stock valued at $2,079,000 after buying an additional 1,105 shares during the last quarter. Beck Mack & Oliver LLC lifted its stake in IDEXX Laboratories by 3.8% during the 4th quarter. Beck Mack & Oliver LLC now owns 2,092 shares of the company's stock valued at $865,000 after acquiring an additional 77 shares in the last quarter. Finally, Capital Research Global Investors lifted its stake in IDEXX Laboratories by 44.4% during the 4th quarter. Capital Research Global Investors now owns 615,996 shares of the company's stock valued at $254,677,000 after acquiring an additional 189,436 shares in the last quarter. 87.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on IDXX. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a report on Monday, April 14th. Barclays boosted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Finally, StockNews.com downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Saturday, April 12th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $523.75.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock traded down $3.54 on Friday, hitting $437.44. 939,265 shares of the stock were exchanged, compared to its average volume of 632,646. The firm's 50 day moving average is $419.93 and its two-hundred day moving average is $429.42. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $548.88. The firm has a market capitalization of $35.45 billion, a PE ratio of 41.00, a P/E/G ratio of 3.41 and a beta of 1.50. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.